Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2007 Jul 5;26(Suppl 1):15–20. doi: 10.1002/clc.4960261306

Comparing HMG‐CoA reductase inhibitors

Peter H Jones 1,✉
PMCID: PMC6653890  PMID: 12539818

Abstract

The statins have proved to be some of the most potent therapies for reducing elevated low‐density lipoprotein (LDL) cholesterol and lessening the risk of coronary heart disease (CHD) and related events. Nonetheless, there are still questions about the clinical relevance of individual drug characteristics, such as chemical derivation, solubility properties, and metabolic route, in terms of tolerability or therapeutic benefit. At the same time, no clear explanation has emerged for the significantly steeper reductions in LDL cholesterol levels achieved with atorvastatin versus lovastatin, simvastatin, pravastatin, or fluvastatin, or, more recently, with rosuvastatin versus atorvastatin, although possible mechanisms have been suggested. More studies are needed to characterize the effects of statins on high‐density lipoprotein (HDL) in different patient groups. Clearly, though, several statins have yielded significant reductions in CHD risk and have shown to be well tolerated in both primary and secondary prevention trials. The possibility that statins exert pronounced effects beyond lowering blood lipids is opening other avenues of research into the benefits of these drugs.

Keywords: coronary heart disease, dyslipidemia, statins

Full Text

The Full Text of this article is available as a PDF (55.9 KB).

References

  • 1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 235: 2486–2497 [DOI] [PubMed] [Google Scholar]
  • 2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc 1998; 279: 1615–1622 [DOI] [PubMed] [Google Scholar]
  • 3. Scandinavian Simvastatin Survival Study Group : Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389 [PubMed] [Google Scholar]
  • 4. Long‐Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group : Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357 [DOI] [PubMed] [Google Scholar]
  • 5. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators : The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009 [DOI] [PubMed] [Google Scholar]
  • 6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307 [DOI] [PubMed] [Google Scholar]
  • 7. Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498–511 [DOI] [PubMed] [Google Scholar]
  • 8. Blumenthal RS: Statins: Effective antiatherosclerotic therapy. Am Heart J 2000; 139: 577–583 [DOI] [PubMed] [Google Scholar]
  • 9. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M: Preclinical and clinical pharmacology of rosuvastatin, a new 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87 (suppl): 28B–32B [DOI] [PubMed] [Google Scholar]
  • 10. Istvan ES, Deisenhofer J: Structural mechanism for statin inhibition of HMG‐CoA reductase. Science 2001; 292: 1160–1164 [DOI] [PubMed] [Google Scholar]
  • 11. Hanefeld M: Clinical rationale for rosuvastatin, a potent new HMG‐CoA reductase inhibitor. Int J Clin Pract 2001; 55: 399–405 [PubMed] [Google Scholar]
  • 12. McCormick AD, McKillop D, Bulters CJ, Miles GS, Baba T, Touchi A, Yamaguchi Y: ZD4522: An HMG‐CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems (abstr 46). J Clin Pharmacol 2000; 40: 1055 [Google Scholar]
  • 13. Jones P, Kafonek S, Laurora I, Hunninghake D: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582–587 [DOI] [PubMed] [Google Scholar]
  • 14. Olsson AG, Pears J, McKellar J, Mizan J, Raza A: Effect of rosuvastatin on low‐density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001; 88: 504–508 [DOI] [PubMed] [Google Scholar]
  • 15. Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, Hutchinson H: Comparison of effects on low‐density lipoprotein cholesterol and high‐density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002; 89: 268–275 [DOI] [PubMed] [Google Scholar]
  • 16. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H: Rosuvastatin demonstrates greater reduction of low‐density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double‐blind study. J Cardiovasc Risk 2001; 8: 383–390 [DOI] [PubMed] [Google Scholar]
  • 17. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA: Hig‐density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8–15 [DOI] [PubMed] [Google Scholar]
  • 18. Jacobs DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA: High‐density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: The follow‐up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990; 131: 32–47 [DOI] [PubMed] [Google Scholar]
  • 19. Yamamoto Y, Gaynor RB: Therapeutic potential of inhibition of the NF‐KB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135–142 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. J Am Med Assoc 1998; 279: 1643–1650 [DOI] [PubMed] [Google Scholar]
  • 21. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals : A randomised placebo‐controlled trial. Lancet 2002; 360: 7–22 [DOI] [PubMed] [Google Scholar]
  • 22. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT: Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289–1298 [DOI] [PubMed] [Google Scholar]
  • 23. Effect of simvastatin on coronary atheroma : The Multicentre Anti‐Atheroma Study (MAAS). Lancet 1994; 344: 633–638 [PubMed] [Google Scholar]
  • 24. Smilde TJ, van den Berkmortel FW, Wollersheim H, van Langem H, Kastelein JJ, Stalenhoef AF: The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest 2000; 30: 473–480 [DOI] [PubMed] [Google Scholar]
  • 25. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. J Am Med Assoc 2001; 285: 1711–1718 [DOI] [PubMed] [Google Scholar]
  • 26. Stenestrand U, Wallentin L: Early statin treatment following acute myocardial infarction and 1‐year survival. J Am Med Assoc 2001; 285: 430–436 [DOI] [PubMed] [Google Scholar]
  • 27. Lefer AM, Scalia R, Lefer DJ: Vascular effects of HMG CoA‐reductase inhibitors (statins) unrelated to cholesterol lowering: New concepts for cardiovascular disease. Cardiovasc Res 2001; 49: 281–287 [DOI] [PubMed] [Google Scholar]
  • 28. Kwak BR, Mach F: Statins inhibit leukocyte recruitment. New evidence for their anti‐inflammatory properties. Arterioscler Thromb Vasc Biol 2001; 21: 1712–1719 [PubMed] [Google Scholar]
  • 29. Takemoto M, Liao JK: Pleitropic effects of 3‐hydroxy‐3‐methyl‐glutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 161: 1405–1410 [DOI] [PubMed] [Google Scholar]
  • 30. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Fumagalli R, Paoletti R, Corsini A: Direct vascular effects of HMG‐CoA reductase inhibitors. Atherosclerosis 1998; 137 (suppl): S101–S109 [DOI] [PubMed] [Google Scholar]
  • 31. Miller SJ: Emerging mechanisms for secondary cardioprotective effects of statins. Cardiovasc Res 2001; 52: 5–7 [DOI] [PubMed] [Google Scholar]
  • 32. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moyé LA, Goldman S, Flaker GC, Braunwald E: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839–844 [DOI] [PubMed] [Google Scholar]
  • 33. Albert MA, Danielson E, Rifai N, Ridker PM, for the PRINCE Investigators : Effect of statin therapy on C‐reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study. J Am Med Assoc 2001; 286: 64–70 [DOI] [PubMed] [Google Scholar]
  • 34. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr, for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators : Measurement of C‐reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959–1965 [DOI] [PubMed] [Google Scholar]
  • 35. Ridker PM: High‐sensitivity C‐reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813–1818 [DOI] [PubMed] [Google Scholar]
  • 36. Jialal I, Stein D, Balis D, Grundy SM, Adams‐Huet B, Devarag S: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C‐reactive protein levels. Circulation 2001; 103: 1933–1935 [DOI] [PubMed] [Google Scholar]
  • 37. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A: Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001; 161: 1405–1410 [DOI] [PubMed] [Google Scholar]
  • 38. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A: Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357–362 [DOI] [PubMed] [Google Scholar]
  • 39. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Heeney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H: Expanded clinical evaluation of lovastatin (EXCEL) study results: I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8,245 patients with moderate hypercholesterolemia. Ann Intern Med 1991; 151: 43–49 [DOI] [PubMed] [Google Scholar]
  • 40. Collins R, Peto R, Armitage J: The MRC/BHF Heart Protection Study: Preliminary results. Int J Clin Pract 2002; 56 (1): 53–56 [PubMed] [Google Scholar]
  • 41. Shepherd J, Hunninghake D, Harris S, Hutchinson H, Pears J: A review of the safety profile of rosuvastatin in an international phase II/III clinical trial programme. Int J Clin Pract 2002; 124 (suppl): 15 [Google Scholar]
  • 42. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin‐gemfibrozil combination therapy. J Am Med Assoc 1990; 264: 71–75 [PubMed] [Google Scholar]
  • 43. Wooltorton E: Bayer pulls cerivastatin (Baycol) from market. Can Med Assoc J 2001; 165: 632 [PMC free article] [PubMed] [Google Scholar]
  • 44. Furberg CD, Pitt B: Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2: 205–207 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Shepherd J: Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety. Eur Heart J 1995; 16: 5–13 [DOI] [PubMed] [Google Scholar]
  • 46. Shek A, Ferrill MJ: Statin‐fibrate combination therapy. Ann Pharmacother 2001; 35: 908–917 [DOI] [PubMed] [Google Scholar]
  • 47. Milionis HJ, Tsapoga TG, Elisaf MS: Another report of acute rhabdomyolysis following cerivastatin monotherapy. Arch Intern Med 2001; 161: 2629–2930 [DOI] [PubMed] [Google Scholar]
  • 48. Pasternak RC, Smith SC Jr, Bairey‐Merz CN, Grundy SM, Cleeman JI, Lenfant C: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567–572 [DOI] [PubMed] [Google Scholar]
  • 49. Blais L, Desgagne A, LeLorier J: 3‐Hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case‐control study. Arch Intern Med 2000; 160: 2363–2368 [DOI] [PubMed] [Google Scholar]
  • 50. Bjerre LM, LeLorier J: Do statins cause cancer? A meta‐analysis of large randomized clinical trials. Am J Med 2001; 110: 716–723 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES